OCEAN BIOMEDICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.55 USD | -4.62% |
|
-10.92% | +134.85% |
| 04-15 | Ocean Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| 03-08 | Ocean Biomedical, Inc. Appoints Amy Griffith as Director | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 105.9 | 110.2 |
| Enterprise Value (EV) 1 | 106 | 111.4 |
| P/E ratio | -2.8 x | -10.5 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | - | - |
| EV / FCF | 4,743,213 x | 20,859,169 x |
| FCF Yield | 0% | 0% |
| Price to Book | -26.2 x | -16.8 x |
| Nbr of stocks (in thousands) | 10,600 | 10,600 |
| Reference price 2 | 9.990 | 10.40 |
| Announcement Date | 11/04/22 | 31/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | -0.232 | -1.652 | -62.34 | -16.12 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.232 | -1.653 | -62.34 | -17.36 |
| Net income 1 | -0.232 | -1.653 | -62.34 | -17.36 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0133 | -0.0947 | -3.565 | -0.9921 |
| Free Cash Flow | - | - | 22.33 | 5.285 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 05/03/21 | 05/03/21 | 11/04/22 | 31/03/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|
| Net sales 1 | - | - | - |
| EBITDA | -5.223 | -2.68 | - |
| EBIT 1 | -5.223 | -2.68 | -2.655 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -67.4 | -13.03 | -14.09 |
| Net income 1 | -67.4 | -13.03 | -14.09 |
| Net margin | - | - | - |
| EPS 2 | -2.720 | -0.4900 | -0.5300 |
| Dividend per Share | - | - | - |
| Announcement Date | 24/05/23 | 14/08/23 | 15/04/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt | - | - | 0.12 | 1.19 |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | 22.3 | 5.28 |
| ROE (net income / shareholders' equity) | - | 156% | 1,459% | 199% |
| ROA (Net income/ Total Assets) | - | - | -16,759% | -1,049% |
| Assets 1 | - | - | 0.372 | 1.655 |
| Book Value Per Share 2 | -0.0100 | -0.1100 | -0.3800 | -0.6200 |
| Cash Flow per Share | - | - | 0 | 0 |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 05/03/21 | 05/03/21 | 11/04/22 | 31/03/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +134.85% | 56.3M | |
| +9.99% | 114B | |
| +12.01% | 107B | |
| -3.07% | 22.22B | |
| -0.67% | 21.28B | |
| -4.64% | 18.8B | |
| -6.90% | 17.51B | |
| -39.36% | 17.17B | |
| +5.82% | 14.14B | |
| +33.05% | 12.2B |
- Stock Market
- Equities
- OCEA Stock
- Financials Ocean Biomedical, Inc.
